Acknowledgement
Jaeyoung Chun has received a research grant and honorarium from Genomictree Inc.
References
- Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol 2017;23:3632-3642. https://doi.org/10.3748/wjg.v23.i20.3632
- Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. https://doi.org/10.1056/NEJMoa1311194
- Fisher DA, Princic N, Miller-Wilson LA, Wilson K, Fendrick AM, Limburg P. Utilization of a colorectal cancer screening test among individuals with average risk. JAMA Netw Open 2021;4:e2122269. https://doi.org/10.1001/jamanetworkopen.2021.22269
- Niedermaier T, Balavarca Y, Brenner H. Stage-specific sensitivity of fecal immunochemical tests for detecting colorectal cancer: systematic review and metaanalysis. Am J Gastroenterol 2020;115:56-69. https://doi. org/10.14309/ajg.0000000000000465
- Dickinson BT, Kisiel J, Ahlquist DA, Grady WM. Molecular markers for colorectal cancer screening. Gut 2015;64:1485-1494. https://doi.org/10.1136/gutjnl-2014-308075
- Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-57. https://doi.org/10.1016/s0046-8177(00)80198-7
- Fatemi N, Tierling S, Es HA, et al. DNA methylation biomarkers in colorectal cancer: clinical applications for precision medicine. Int J Cancer 2022;151:2068-2081. https://doi.org/10.1002/ijc.34186
- Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol 2021;116:458-479. https://doi.org/10.14309/ajg.0000000000001122
- Naber SK, Knudsen AB, Zauber AG, et al. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS One 2019;14:e0220234. https://doi.org/10.1371/journal.pone.0220234
- Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology 2016;151:427-439.e6. https://doi.org/10.1053/j.gastro.2016.06.003
- Cotter TG, Burger KN, Devens ME, et al. Long-term follow-up of patients having false-positive multitarget stool DNA tests after negative screening colonoscopy: the LONG-HAUL cohort study. Cancer Epidemiol Biomarkers Prev 2017;26:614-621. https://doi.org/10.1158/1055-9965.EPI-16-0800
- Oh TJ, Oh HI, Seo YY, et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 2017;9:126. https://doi.org/10.1186/s13148-017-0426-3
- Han YD, Oh TJ, Chung TH, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics 2019;11:51. https://doi.org/10.1186/s13148-019-0642-0
- Yeoh KG, Ho KY, Chiu HM, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut 2011;60:1236-1241. https://doi.org/10.1136/gut.2010.221168
- Chiu HM, Ching JY, Wu KC, et al. A risk-scoring system combined with a fecal immunochemical test is effective in screening high-risk subjects for early colonoscopy to detect advanced colorectal neoplasms. Gastroenterology 2016;150:617-625.e3. https://doi.org/10.1053/j.gastro.2015.11.042
- Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol 2023;21:604-616. https://doi.org/10.1016/j.cgh.2022.12.008
- Bosch LJW, de Wit M, Pham TV, et al. Novel stool-based protein biomarkers for improved colorectal cancer screening: a case-control study. Ann Intern Med 2017;167:855-866. https://doi.org/10.7326/M17-1068
- Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 2019;25:679-689. https://doi.org/10.1038/s41591-019-0406-6
- Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70-78. https://doi.org/10.1136/gutjnl-2015-309800
- Liang JQ, Wong SH, Szeto CH, et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J Gastroenterol Hepatol 2021;36:1035-1043. https://doi.org/10.1111/jgh.15171
- Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317-325. https://doi.org/10.1136/gutjnl-2012-304149
- Jin P, Kang Q, Wang X, et al. Performance of a secondgeneration methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 2015;30:830-833. https://doi.org/10.1111/jgh.12855
- Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by wholegenome sequencing of plasma cell-free DNA. BMC Cancer 2019;19:832. https://doi.org/10.1186/s12885-019-6003-8
- Lee J, Kim HC, Kim ST, et al. Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC). J Clin Oncol 2021;39(15 Suppl):3536. https://doi.org/10.1200/JCO.2021.39.15_suppl.3536